The National Institute of Mental Health convened an international group of experts to examine the conduct of treatment trials for persons with borderline personality disorder (BPD). The rapid growth of treatment research had led to the recognition that investigators face unique methodological issues with these challenging patients.
Methods
Conference members reviewed critical aspects of psychotherapy and pharmacotherapy trial design for patients with BPD.
Results
This article summarizes discussions held on March 17-18, 2005.
Conclusion
This paper addresses the most pressing issues in sample selection and trial design pertaining to BPD; issues that have bedeviled both investigators submitting applications and reviewers trying to assess the merit of these grants. By disseminating this work, conference members hope to make this process more consistent and productive for all concerned.
CowdryRGardnerDL. Pharmacotherapy of borderline personality disorder-alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111–119.
4.
SalzmanCWolfsonANSchatzbergA. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23–29.
5.
SoloffPHGeorgeANathanS. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238–246.
6.
SoloffPHCorneliusJGeorgeA. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377–385.
7.
BogenschutzMPNurnbergGH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104–109.
8.
FrankenburgFRZanariniMC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442–446.
9.
HollanderEAllenALopezRP. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199–203.
10.
HollanderESwannACCoccaroEF. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621–624.
11.
LoewTHNickelMKMuehlbacherM. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo study. J Clin Psychopharmacol. 2006;26:61–66.
12.
NickelMKNickelCMitterlehnerFO. Topiramate treatment of aggression in female borderline personality disorder patients: a double blind placebo-controlled study. J Clin Psychiatry. 2004;65: 1515–1519.
13.
NickelMKNickelCKaplanP. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495–499.
14.
RinneTvan den BrinkW, WoutersL, . SSRI treatment of borderline personality disorder: a randomized placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048–2054.
15.
SchulzSCCamlinKLBerryS. Risperidone for borderline personality disorder: A double-blind study. Presented at Annual Meeting of the American College of Neuropsychopharmacology. Nashville, TN, 1999.
16.
SolerJPascualJCCampinsJ. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221–1224.
17.
TrittKNickelCLahmannC. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287–291.
18.
ZanariniMCFrankenburgFR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849–854.
19.
ZanariniMCFrankenburgFR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167–169.
20.
ZanariniMCFrankenburgFRParachiniEA. A preliminary randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903–907.
21.
LinehanMMArmstrongHESuarezA. Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry. 1991; 48:1060–1064.
22.
BatemanA, FonagyP.Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry.1999;156:1563–1569.
23.
BlumN St. JohnD, PfohlB, . Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry. 2008;165:468–478.
24.
BohusMHaafBStiglmayrC. Evaluation of inpatient dialectical-behavioral therapy for borderline personality disorder—a prospective study. Behav Res Ther. 2000;38:875–887.
25.
ClarkinJFLevyKNLenzenwegerMF. Evaluating three treatments for borderline personality: a multiwave study. Am J Psychiatry. 2007;164:922–928.
26.
DavidsonKNorrieJTyrerP. The effectiveness of cognitive behavior therapy for borderline personality disorder: results from the borderline personality disorder study of cognitive therapy (BOSCOT) trial. J Pers Disord. 2006;20:450–465.
27.
FarrellJMShawIAWebberMA. A schema-focused approach to group psychotherapy for outpatients with borderline personality disorder: a randomized controlled trial. J Behav Ther Exp Psychiatry. 2009;40:317–328.
28.
Giesen-BlooJvan DyckR, SpinhovenP, . Outpatient psychotherapy for borderline personality disorder. Arch Gen Psychiatry. 2006;63:649–658.
29.
KoonsCRRobinsCJTweedJL. Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. Behavior Therapy. 2001;32:371–390.
30.
LinehanMMSchmidtH3rd, DimeffLA, . Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict. 1999;8:279–292.
31.
LinehanMMDimeffLAReynoldsSK. Dialectical behavior therapy versus comprehensive validation plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend. 2002;67:13–26.
32.
LinehanMMComtoisKAMurrayAM. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs. therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry. 2006;63:757–766.
33.
TurnerRM. Naturalistic evaluation of dialectical behavior therapy-oriented treatment for borderline personality disorder. In: TurnerRM, MarlattGA, AlbanoAM, eds. Cognitive and behavioral practice, special series dialectical behavior therapy: Adaptations and new applications.New York, NY: Association for Advancement of Behavior Therapy; 2000:413–419
34.
VerheulRVan Den BoschLM, KoeterMW, . Dialectical behavior therapy for women with borderline personality disorder: 12-month randomized clinical trial in The Netherlands. Br J Psychiatry. 2003;182:135–140.
35.
ZanariniMCFrankenburgFR. A preliminary randomized trial of psychoeducation for women with borderline personality disorder. J Pers Disord. 2008;22:284–290.
36.
StanglDPhoflBZimmermanM. A structured interview for the DSM-III personality disorders. A preliminary report. Arch Gen Psychiatry. 1985;42:591–596.
37.
LorangerAWSusmanVLOldhamJM. The Personality Disorder Examination: a preliminary report. J Pers Disord. 1987;1:1–13.
38.
ZanariniMCFrankenburgFRChaunceyDL. The diagnostic Interview for Personality Disorders: interrater and test-retest reliability. Compr Psychiatry. 1987;28:467–480.
39.
FirstMBSpitzerRLGibbonMWilliamsJBW. The Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). Part II: multisite test-retest reliability study. J Pers Disord. 1995;9:92–104.
40.
ZanariniMCGundersonJGFrankenburgFR. The revised diagnostic interview for borderlines: discriminating BPD from other Axis II disorders. J Pers Disord. 1989;3:10–18.
41.
ZanariniMCFrankenburgFRVujanovicAA. Inter-rater and test-retest reliability of the Revised Diagnostic Interview for Borderlines. J Pers Disord. 2002;16:270–276.
42.
ZanariniMCSilkKR. Dilemmas in the treatment of severe borderline personality disorder. In: DewanMJ, PiesR. eds. The difficult-to-treat psychiatric patient.Arlington, VA: American Psychiatric Publishing, Inc.; 2001.
43.
GundersonJG. Borderline personality disorder. Washington DC: American Psychiatric Press; 1984.
44.
Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
45.
GuyW.ECDEU assessment manual for psychopharmacology. RockvilleMD: U.S. Department of Health, Education, and Welfare; 1978:217–222.
46.
ZanariniMCVujanovicAAParachiniE. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): A continuous measure of DSM-IV borderline psychopathology. J Pers Disord. 2003;17: 233–242.
47.
ZanariniMCFrankenburgFR. Attainment and maintenance of reliability of axis I and II disorders over the course of a longitudinal study. Compr Psychiatry. 2001;42:369–374.
48.
PfohlBBlumNMcCormickB. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a new scale to measure severity and change in borderline personality disorder. J Pers Disord. 2009;23:281–293.
49.
ArntzAvan den HoornM, CornelisJ, . Reliability and validity of the borderline personality disorder severity index. J Pers Disord. 2003;17:45–59.
50.
McGlashanTHGriloCMSkodolAE. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic co-occurrence. Acta Psychiatr Scand. 2000;102:256–264.
51.
ZanariniMCFrankenburgFRDuboED. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155:1733–1739.
52.
ZimmermanMMattiaJI. Axis I diagnostic comorbidity and borderline personality disorder. Compr Psychiatry. 1991;40:245–252.
53.
KoenigsbergHWReynoldsDGoodmanM. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628–634.
54.
BenderDSDolanRTSkodolAE. Treatment utilization by patients with personality disorders. Am J Psychiatry. 2001;158:295–302.
55.
ZanariniMCFrankenburgFRHennenJ. Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for 6 years. J Clin Psychiatry. 2004;65:28–36.
56.
FrankenburgFRZanariniMC. The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization. J Clin Psychiatry. 2004;65:1660–1665.
57.
BohusMLimbergerMFFrankU. Psychometric properties of the Borderline Symptom List (BSL). Psychopathology. 2007;40:126–132.
58.
FrankJ.Therapeutic factors in psychotherapy. Am J Psychother. 1971;25:350–361.
GabbardGO. Do all roads lead to Rome? New findings on borderline personality disorder. Am J Psychiatry. 2007;164:853–855.
61.
BaskinTWTierneySCMinamiT. Establishing specificity in psychotherapy: a meta-analysis of structural equivalence of placebo controls. J Consult Clin Psychol. 2003;71:973–979.
62.
GratzKLGundersonJG. Preliminary data on an acceptance-based emotion regulation group intervention for deliberate self-harm among women with borderline personality disorder. Behav Ther. 2006;37: 25–35.
63.
WeinbergIGundersonJGHennenJ. Manual assisted cognitive treatment for deliberate self-harm in borderline personality disorder patients. J Pers Disord. 2006;20:482–492.
64.
LivesleyWJ. A framework for integrating dimensional and categorical classifications of personality disorder. J Pers Disord. 2007;21:199–224.
65.
CostaPTMcCraeRR. Professional Manual: Revised NEO Personality Inventory (NEO PI-R) and NEO Five Factor Inventory (NEO-FFI). Odessa, FL: Psychological Assessment Resources; 1992.
66.
ClarkLA. Manual for the Schedule for Nonadaptive and Adaptive Personality (SNAP). Minneapolis, MN: University of Minnesota Press; 1993.
67.
LivesleyWJJacksonDN. Manual for the Dimensional Assessment of Personality Problems - basic questionnaire (DAPP-BQ). Port Huron, MI: Sigma Assessment Systems; 2005-2007.
